Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SAR302503 versus placebo in myelofibrosis with splenomegaly
2011-001897-25Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fedratinib in primary myelofibrosis (PMF) and myelofibrosis (MF) (3 arms), sponsored by Sanofi. Primary endpoint: Response Rate. Started Aug 2011; status: terminated.
02
Drugs
fedratinib
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2011-001897-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001897-25.